Safety and Targeting of Anti-hk2 Antibody in mCRPC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04116164 |
|
Recruitment Status :
Recruiting
First Posted : October 4, 2019
Last Update Posted : October 4, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC.
This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In) radiolabeled h11B6 in subjects with advanced prostate cancer. This study will also provide the dosimetric information crucial for Phase 1 therapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Castration-Resistant Prostatic Cancer Metastatic Disease | Drug: 111In-DOTA-h11B6 | Early Phase 1 |
It is the intent to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This Phase 0 study will be conducted to confirm the safety, estimate the mass amount, and confirm in vivo tumor targeting of the antibody. This study will use Indium-111 (111In) radiolabeled h11B6 in subjects with mCRPC to image known sites of disease and identify a favorable mass amount of antibody for satisfactory tumor targeting with minimal/no accumulation off-target. In cohort 1, In-111 labeled h11B6 will remain fixed at 2 mg, and additional h11B6 will be added in 2 sub-cohorts (8 mg and 18 mg respectively); up to 6 patients may be entered into a sub-cohort. Additional patients (up to 6) will be studied once the most favorable mass and imaging time point have been established, to establish targeting of antibody to known disease.
This study will provide the dosimetric information crucial for Phase 1 therapy.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 18 participants |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | 3-6 patients will be studied in each of 3 sub-cohorts to determine the most favorable mass amount of h11B6 (2 mg, 10 mg, 20 mg). An additional 6 patients will be imaged at the most favorable mass amount to assess tumor targeting. |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer. |
| Actual Study Start Date : | September 18, 2019 |
| Estimated Primary Completion Date : | June 30, 2020 |
| Estimated Study Completion Date : | July 31, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Dosimetry and targeting
Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively. In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determined from cohort 1, and will be imaged at one time-point |
Drug: 111In-DOTA-h11B6
4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6. |
- Serum pharmacokinetics [ Time Frame: 6 months ]Serum clearance kinetics of 111In-DOTA-h11B6, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).
- Radioactivity Biodistribution [ Time Frame: 6 months ]Radioactivity residence times in liver, kidneys and tumor, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).
- Radioactivity accumulation in known tumor sites [ Time Frame: 9 months ]Number of known metastatic lesions in which there is increased uptake of 111In, in both cohorts 1 and 2.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | The study is being carried out in prostate cancer which afflicts only men. |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with mCRPC will be eligible if they meet the following criteria:
- Eastern Cooperative Oncology Group (ECOG) ≤ 1
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Castrate levels of testosterone (<50 ng/dL [1.74 nmol/L])
- Metastatic disease documented by imaging
- Documented progressive mCRPC with androgen involvement as defined by - Prostate Cancer Working Group 3
- Acceptable laboratory parameters
- At least 28 days since administration of any therapeutic radioactive isotope
- Able to tolerate the conditions required to perform imaging studies (e.g., lying flat for at least 1 hour).
Exclusion Criteria:
- Known hypersensitivity to proteins, or other allergic diathesis that, in the opinion of the investigator, makes an immune response to humanized antibody likely
- Radiotherapy or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of study agent
- Any condition that, in the opinion of the Investigator, would impair the subject's ability to comply with study procedures and required study visits
- Active, symptomatic, or untreated brain metastases.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04116164
| Contact: Michael J Morris, MD | 646-497-9068 | morrism@mskcc.org | |
| Contact: Neeta Pandit-Taskar, MD | 212-639-3046 | pandit-n@mskcc.org |
| United States, New York | |
| Memorial Sloan-Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10021 | |
| Contact: Michael J Morris, MD 646-497-9068 morrism@mskcc.org | |
| Contact: Neeta Pandit-Taskar, MD 212-639-3049 pandit-n@mskcc.org | |
| Principal Investigator: | Michael J Morris, MD | Memorial Hospital for Cancer and Allied Diseases |
Publications:
| Responsible Party: | Tomopath Inc. |
| ClinicalTrials.gov Identifier: | NCT04116164 History of Changes |
| Other Study ID Numbers: |
GID5490 |
| First Posted: | October 4, 2019 Key Record Dates |
| Last Update Posted: | October 4, 2019 |
| Last Verified: | October 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Radiolabeled antibody Imaging |
|
Neoplasm Metastasis Prostatic Neoplasms Prostatic Neoplasms, Castration-Resistant Neoplastic Processes Neoplasms Pathologic Processes Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Genital Diseases, Male Prostatic Diseases Antibodies Immunoglobulins Immunoconjugates Immunologic Factors Physiological Effects of Drugs |